UY27675A1 - Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2 - Google Patents

Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2

Info

Publication number
UY27675A1
UY27675A1 UY27675A UY27675A UY27675A1 UY 27675 A1 UY27675 A1 UY 27675A1 UY 27675 A UY27675 A UY 27675A UY 27675 A UY27675 A UY 27675A UY 27675 A1 UY27675 A1 UY 27675A1
Authority
UY
Uruguay
Prior art keywords
inhibitor
combinations
selective
cyclooxygenasa
alfa
Prior art date
Application number
UY27675A
Other languages
English (en)
Spanish (es)
Inventor
Charles P Taylor Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY27675A1 publication Critical patent/UY27675A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
UY27675A 2002-02-22 2003-02-19 Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2 UY27675A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
UY27675A1 true UY27675A1 (es) 2003-09-30

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27675A UY27675A1 (es) 2002-02-22 2003-02-19 Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2

Country Status (21)

Country Link
US (1) US20030199567A1 (enExample)
EP (1) EP1480639A1 (enExample)
JP (1) JP2005523281A (enExample)
KR (1) KR20040085216A (enExample)
CN (1) CN1635887A (enExample)
AR (1) AR038531A1 (enExample)
AU (1) AU2003246864A1 (enExample)
BR (1) BR0307906A (enExample)
CA (1) CA2476438A1 (enExample)
CO (1) CO5611109A2 (enExample)
HN (1) HN2003000071A (enExample)
IL (1) IL162932A0 (enExample)
MX (1) MXPA04008175A (enExample)
NO (1) NO20043947L (enExample)
PA (1) PA8567201A1 (enExample)
PE (1) PE20031052A1 (enExample)
PL (1) PL372210A1 (enExample)
RU (1) RU2286151C2 (enExample)
TW (1) TW200303214A (enExample)
UY (1) UY27675A1 (enExample)
WO (1) WO2003070237A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
CA2537402C (en) * 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1682149B1 (en) * 2003-10-23 2009-12-02 Medtronic, Inc. Injectable gabapentin compositions
KR20080109915A (ko) * 2006-04-11 2008-12-17 노파르티스 아게 유기 화합물
EP2124913A1 (en) * 2006-12-22 2009-12-02 Novartis AG 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors
WO2009137052A1 (en) * 2008-05-05 2009-11-12 Winthrop University Hospital Method for improving cardiovascular risk profile of cox inhibitors
CN105520924B (zh) * 2008-09-05 2019-04-09 格吕伦塔尔有限公司 3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和抗癫痫药的联合药物
KR102631399B1 (ko) * 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
CN116782897A (zh) * 2020-10-28 2023-09-19 特默罗制药股份有限公司 水不溶性的cox-2抑制剂的水性制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
HU0102040D0 (en) * 1994-07-27 2001-07-30 Warner Lambert Co Purified gabapentine binding protein
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
ATE311867T1 (de) * 1997-09-08 2005-12-15 Warner Lambert Co Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
TR200001800T2 (tr) * 1997-12-16 2001-03-21 Warner-Lambert Company -4(3)-İkameli -4(3)- aminometil-(tio) piran veya- piperidin türevleri (=Gabapentin analogları), hazırlanmaları ve nörolojik hastalıkların tedavisinde kullanımları
JP2002538221A (ja) * 1999-03-10 2002-11-12 ワーナー−ランバート・カンパニー 抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
WO2001041761A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Valdecoxib compositions

Also Published As

Publication number Publication date
PL372210A1 (en) 2005-07-11
TW200303214A (en) 2003-09-01
RU2286151C2 (ru) 2006-10-27
PE20031052A1 (es) 2003-12-24
RU2004125609A (ru) 2006-01-27
CA2476438A1 (en) 2003-08-28
JP2005523281A (ja) 2005-08-04
IL162932A0 (en) 2005-11-20
US20030199567A1 (en) 2003-10-23
PA8567201A1 (es) 2003-11-12
HN2003000071A (es) 2003-11-24
EP1480639A1 (en) 2004-12-01
KR20040085216A (ko) 2004-10-07
MXPA04008175A (es) 2004-11-26
AR038531A1 (es) 2005-01-19
BR0307906A (pt) 2004-12-21
WO2003070237A1 (en) 2003-08-28
AU2003246864A1 (en) 2003-09-09
CO5611109A2 (es) 2006-02-28
CN1635887A (zh) 2005-07-06
NO20043947L (no) 2004-09-21

Similar Documents

Publication Publication Date Title
UY27675A1 (es) Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2
PA8592101A1 (es) Nuevos enantiomeros (r) y (s) de derivados del acido tiofeno hidroxamico
AR022023A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados del acido fibrico para prescripciones cardiovasculares
AR022022A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con agentes secuestrantes de acido biliar, para prescripciones cardiovasculares
AR046970A1 (es) Esteres de fosfato de florfenicol
EA200100958A1 (ru) Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2
BR0306675A (pt) Dispositivo para prover um número de produtos
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
MX2021010875A (es) Composiciones de éster de ácido cannabinoide y sus usos.
MX2024002885A (es) Inhibidor de la proteasa 3clpro.
CL2007002297A1 (es) Medio para enlazar una correa transportadora central de una maquina procesadora de pescado, que comprende un campo de almacenaje intermedio con compartimientos individuales separados por lenguetas o placas y una unidad de segmentos; instalacion y metodo para procesamiento de pescado.
UY28076A1 (es) Procedimiento para aumentar el rendimiento de las leguminosas.
HN2003000040A (es) Acidos 3-(imidazolil)-2-aminopropanoicos
CY1121477T1 (el) Χρηση αλφα-κετογλουταρικου οξεος και 5-υδροξυ-μεθυλοφουρφουραλης για τη μειωση του οξειδωτικου στρες
MXPA04001398A (es) Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo.
BR0011801A (pt) Inibidores de benzamida substituìda para 3c protease de rinovìrus
MX2020001484A (es) Inhibidores bicíclicos de la histona desacetilasa.
AR021241A1 (es) Inhibidores de proteasas
DOP2003000577A (es) Combinaciones de un ligando alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2
MXPA05009902A (es) Formulaciones topicas foto-estabilizadas de ketoprofeno que contienen dos filtros uv.
CL2023003168A1 (es) Moduladores de trex1
EP4228114C0 (en) Electricity supply system
AR012286A1 (es) Ciclopeptolidos
UA46764S (uk) 1. комплект етикеток
UA45242S (uk) 1.-2. комплект етикеток

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150520